The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects

Thrombosis Research

Volumn 88, Issue 5, 1997, Pages 399-407

  Naran, Nitien H ^a   Chetty, Nanthakumarn ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

cAMP; Hypercholesterolaemia; Platelet function; Ridogrel; Thromboxane

Indexed keywords

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; CYCLIC AMP; PROSTAGLANDIN ENDOPEROXIDE; RIDOGREL; THROMBIN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE B2; THROMBOXANE SYNTHASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ADULT; BLOOD PLATELETS; ENZYME INHIBITORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; PENTANOIC ACIDS; PLATELET AGGREGATION INHIBITORS; PYRIDINES; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANE-A SYNTHASE;

EID: 0031461963     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00271-5     Document Type: Article

References (41)

1. Kotzé MJ, Langenhoven E, Warnich L, Du Plessis L, Marx MP, Oosthuizen CJJ, Retief AE The identification of two low-density lipoprotein receptor gene mutations in South African familial hypercholesterolaemia. S Afr Med J. 76:1989;399-401.
2. Leitersdorf E, Van Der Westhuyzen DR, Coetzee GA, Hobbs HH. Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolaemia in Afrikaners. J Clin Invest 1989;84:954-61.
3. Kotzé MH, Warnich L, Langenhoven E, Du Pleissis L, Retief AE An exon 4 mutation identified in the majority of South African familial hypercholesterolaemics. J Med Genet. 27:1990;298-302.
4. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolaemia. Hum Mutat 1992;1:445-66.
5. Fredrickson DS, Goldstein JL, Brown MS. The familial hyperlipoproteinemias. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, editors. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill; 1978. p. 624.
6. Slack J. Risks of ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet 1969;ii:1380-2.
7. Jensen J. Blankenhorn DH, Kornerup V. Coronary disease in familial hypercholesterolaemia. Circulation 1967;36:77-82.
8. Carvalho ACA, Colman RW, Lees RS. Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia. Circulation 1974;50:570-4.
9. Shattil SJ, Anaya-Galindo R, Bennett J. Colman RW, Cooper RA. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975;55:636-43.
10. Colman RW. Platelet function in hyperbetalipoproteinemia. Thromb Haemost 1978;39:284-93.
11. Bradlow BA, Chetty N, Birnhaum M, Baker SG, Seftel HC. Platelet function in familial hypercholesterolaemia in South Africa and the effect of probucol. Thromb Res 1982;26:91-9.
12. Aviram M. Platelets and the vessel wall lesion. Curr Opin Lipidol 1992;3:344-8.
13. Chetty N, Naran NH Platelet hyperreactivity in hyperlipidaemia with specific reference to platelet lipids and fatty acid composition. Clin Chim Acta. 213:1992;1-13.
14. Bizios R, Wong LK, Vaillancourt R, Lees RS, Carvalho ACA Platelet prostaglandin endoperoxide formation in hyperlipidemia (Abstract). Thromb Haemost. 38:1977;288.
15. Tremoli E, Folco G, Agardi E, Galli C. Platelet thromboxane and serum-cholesterol. Lancet 1979;1:107-8.
16. Joist JH, Kendal-Baker R, Schonfield G Increased in vivo and in vitro platelet function in type II and type IV hyperlipoproteinaemia. Thromb Res. 15:1979;94-108.
17. Zahavi J, Betteridge DJ, Hones NAG, Galton DJ, Leyton J, Kakkar VV Beta-thromboglobulin platelet factor 4 and malondialdehyde formation in hyperlipidemic patients (Abstract). Thromb Haemost. 42:1979;424.
18. Wu KK, Armstrong ML, Hoak JC, Megan MB. Platelet aggregates in hypercholesterolaemic rhesus monkeys. Thromb Res 1975;7:917-25.
19. Baldassarre D, Mores N, Colli S, Pazzucconi F, Sirtori CR, Tremoli E. Platelet alpha 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation. Clin Pharmacol Ther 1997;61:684-91.
20. Harker LA, Ritchi JL. The role of platelets in acute vascular events. Circulation 1980;61:V13-8.
21. Carvalho ACA, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974;290:434-8.
22. Mosconi C, Colli S, Tremoli E, Galli C. Phosphatidylinositol (PI) and PI-associated arachidonate are elevated in platelet total membranes of type IIa hypercholesterolaemic subjects. Atherosclerosis 1988;72:129-34.
23. Yamamoto A. Management of patients with hypercholesterolemia. In: Tanphaichitr V, Dahlen W, Suphakarn V, Valyseri A, editors. Human Nutrition: Better Nutrition, Better Life. Bangkok: Aksornsmai Press; 1984. pp. 82-7.
24. Yamamoto A, Yokoyama S, Yamamura T. Combined drug treatment and plasmapheresis for familial hypercholesterolemia. In: Fears R, editor. Pharmacalogical Control of Hyperlipidemia. Barcelona: Prous Science Publishers; 1986. pp. 333-42.
25. Renaud S, Morazain R, Sauvanet JP, Dumont E, Drouin P Influence of a hypolipemic drug (procetofene) on platelet functions and lipid composition in type IIb hyperlipoproteinemia. Haemostasis. 8:1979;82-95.
26. Yamamoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T. Effect of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis 1983; 48:157-66.
27. Wessler S. Drug prophylaxis for arterial thromboembolism. JAMA 1981;246:2484-7.
28. 2/prostaglandin endoperoxide receptor blockade in one molecule. I Thromb Haemost. 61:1989;35-42.
29. 2/prostaglandin endoperoxide receptor blockade in one molecule - II. Pharmacological effect in vitro and ex-vivo. Thromb Haemost 1989;61:43-9.
30. Chetty N, Naran NH Platelet function in cholesterol-enriched platelets and the effect of ridogrel, aspirin and indomethacin. Eur J Lab Med. 3:1995;99-106.
31. Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol 1975;228:1757-65.
32. Lawrie JS, Ross J, Kemp GD. Purification of fibrinogen and the separation of its degradation products in the presence of calcium ions. Biochem Soc Trans 1979;7:693-4.
33. Molnar J, Lorand L. Studies on apyrases. Arch Biochem Biophys 1961;93:353-63.
34. Aster RH, Jandl JH. Platelet sequestration in man. I Methods. J Clin Invest 1964;43:843-50.
35. Ardlie NG, Perry DW, Packham MA, Mustard JF. Influence of apyrase on stability of suspensions of washed rabbit platelets. Proc Soc Exp Bio med 1971;136:1021-3.
36. 2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987;70:647-51.
37. Greenberg J, Packham MA, Cazenave JP, Reimers HJ, Mustard JF. Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 1975;32:476-84.
38. Packham MA, Kinlough-Rathbone RL, Reimbers HJ, Scott S, Mustard JF. Mechanisms of platelet aggregation independent of adenosine diphosphate. In: Silver MH, Kocsis JJ, editors. Prostaglandin in Hematology. New York: Spectrum Publication Inc.; 1977. pp. 247-76.
39. Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989;74:1185-95.
40. Hoet B, Arnout J, Deckmyn H, Vermylen J. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor. Thromb Haemost 1993;70:822-5.
41. Hoet B, Falcon C, De Reys S, Arnout J, Deckmyn H, Vermylen J. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthetase inhibitor, inhibits human platelet activation in vitro and in vivo: A comparison with aspirin. Blood 1990;75:646-53.